Fresenius Medical Care AG (NYSE:FMS) saw strong trading volume on Wednesday . 175,713 shares traded hands during trading, a decline of 7% from the previous session’s volume of 188,089 shares.The stock last traded at $44.60 and had previously closed at $43.76.

Several equities research analysts have recently issued reports on the company. Robert W. Baird reaffirmed a “hold” rating on shares of Fresenius Medical Care AG in a research report on Monday, May 16th. DZ Bank AG reaffirmed a “sell” rating on shares of Fresenius Medical Care AG in a research report on Tuesday, May 10th. Zacks Investment Research upgraded Fresenius Medical Care AG from a “sell” rating to a “hold” rating in a research note on Wednesday, May 4th. Royal Bank Of Canada reiterated a “hold” rating on shares of Fresenius Medical Care AG in a research note on Tuesday, May 24th. Finally, Sanford C. Bernstein began coverage on Fresenius Medical Care AG in a research note on Monday, April 11th. They set an “outperform” rating for the company. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating and six have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $42.50.

The company has a 50-day moving average of $42.81 and a 200 day moving average of $42.81. The company has a market capitalization of $27.34 billion and a price-to-earnings ratio of 26.05.

Fresenius Medical Care AG (NYSE:FMS) last issued its quarterly earnings data on Tuesday, May 3rd. The company reported $0.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.42 by $0.33. The company had revenue of $4.21 billion for the quarter, compared to analysts’ expectations of $4.25 billion. The company’s revenue for the quarter was up 6.2% on a year-over-year basis. During the same quarter last year, the company earned $0.69 earnings per share. Analysts expect that Fresenius Medical Care AG will post $2.03 earnings per share for the current year.

A number of large investors recently modified their holdings of FMS. Commerzbank Aktiengesellschaft FI increased its stake in shares of Fresenius Medical Care AG by 46.1% in the fourth quarter. Commerzbank Aktiengesellschaft FI now owns 38,351 shares of the company’s stock worth $1,605,000 after buying an additional 12,105 shares during the period. US Bancorp DE increased its stake in shares of Fresenius Medical Care AG by 4.0% in the fourth quarter. US Bancorp DE now owns 274,935 shares of the company’s stock worth $11,503,000 after buying an additional 10,479 shares during the period. Comerica Bank increased its stake in shares of Fresenius Medical Care AG by 5.4% in the fourth quarter. Comerica Bank now owns 35,387 shares of the company’s stock worth $1,486,000 after buying an additional 1,798 shares during the period. WBI Investments Inc. bought a new stake in shares of Fresenius Medical Care AG during the fourth quarter worth about $2,249,000. Finally, Neuberger Berman Group LLC increased its stake in shares of Fresenius Medical Care AG by 8.2% in the fourth quarter. Neuberger Berman Group LLC now owns 35,128 shares of the company’s stock worth $1,470,000 after buying an additional 2,649 shares during the period.

Fresenius Medical Care AG & Co KGaA (FMC AG & CO. KGAA) is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end stage renal disease (ESRD), as well as other healthcare services. The Company operates through four segments: North America, Europe, Middle East, Africa (EMEA), Asia-Pacific and Latin America.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.